Valuation: PREDILIFE

Market Cap 41.44L 47.29L 47.29L 38.47L 35.35L 66.61L 46Cr 67.59L 4.58Cr 1.79Cr 22Cr 1.78Cr 1.74Cr 77Cr P/E 2024
-3.18x
P/E 2025 -3.01x
Enterprise Value 89.21L 1.02Cr 1.02Cr 82.82L 76.1L 1.43Cr 98Cr 1.46Cr 9.87Cr 3.86Cr 48Cr 3.82Cr 3.74Cr 166.07Cr EV / Sales 2024
34.5x
EV / Sales 2025 19.3x
Free-Float
48.75%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2004
Chief Tech/Sci/R&D Officer - 01/01/2007
General Counsel - 01/01/2016
Director TitleAgeSince
Chairman 56 01/01/2004
Director/Board Member 46 01/01/2018
Director/Board Member 58 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-.--%+116.94%+10.40% 2TCr
-2.55%+2.45%+151.89%+102.97% 475.01Cr
-2.79%+2.43%+112.90%+171.66% 361.38Cr
-5.66%+31.55%+107.63%-32.59% 244.68Cr
+2.01%+3.82%-26.08%-35.34% 208.33Cr
-1.97%+30.59%+196.31%+255.41% 199.1Cr
0.00%+9.06%+198.32%-43.20% 104.73Cr
-1.10%-2.71%-13.50%+25.12% 84Cr
-0.14%+1.86%-36.72%-14.16% 49Cr
Average -1.25%+8.34%+89.74%+48.92% 414.33Cr
Weighted average by Cap. -0.48%+5.43%+113.96%+44.02%

Financials

2024 2025
Net sales 5L 6L 6L 5L 4L 8L 5.43Cr 8L 54.54L 21.35L 2.66Cr 21.13L 20.67L 9.18Cr 8L 10L 10L 8L 7L 13.44L 9.2Cr 13.63L 92.43L 36.18L 4.5Cr 35.81L 35.04L 16Cr
Net income -42.65L -48.67L -48.67L -39.59L -36.38L -68.55L -47Cr -69.56L -4.72Cr -1.85Cr -23Cr -1.83Cr -1.79Cr -79Cr -39.34L -44.9L -44.9L -36.53L -33.56L -63.25L -43Cr -64.18L -4.35Cr -1.7Cr -21Cr -1.69Cr -1.65Cr -73Cr
Net Debt 35.38L 40.38L 40.38L 32.85L 30.19L 56.88L 39Cr 57.72L 3.91Cr 1.53Cr 19Cr 1.52Cr 1.48Cr 66Cr 47.78L 54.53L 54.53L 44.35L 40.76L 76.8L 53Cr 77.93L 5.28Cr 2.07Cr 26Cr 2.05Cr 2Cr 89Cr
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
-